Daptomycin-Nonsusceptible, Vancomycin-Intermediate, Methicillin-ResistantStaphylococcus aureusEndocarditis Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Due to the emergence ofStaphylococcus aureuswith reduced vancomycin susceptibility, newer antibiotics, including daptomycin, have been used to treat methicillin-resistantS aureusinfections. Daptomycin is a cyclic lipopeptide that is approved to treatS aureusbacteremia and right-sided endocarditis, and reports ofS aureuswith reduced susceptibility to daptomycin are infrequent. To our knowledge, the present report describes the first Canadian case of daptomycin-nonsusceptible, vancomycin-intermediateS aureusinfection.

publication date

  • 2012